WuXi Biologics bags service agreement with BioNTech

11 January 2024

China-based contract research, development and manufacturing organization (CRDMO) WuXi Biologics (2269: HK) saw its shares jump nearly 9% to HK$30.45 by close of trading today, after it announced a new collaboration.

WuXi has signed a research service agreement with German biotech BioNTech (Nasdaq: BNTX), which is pioneering novel mRNA therapies for cancer and other serious diseases, and, in partnership with Pfizer (NYSE: PFE), developed the most successful COVID-10 vaccine Comirnaty).

Under the terms of the agreement, WuXi leverages its proprietary antibody discovery technology platforms to discover two undisclosed targets of pre-clinical investigational monoclonal antibodies for BioNTech to develop next-generation therapeutic product candidates.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK